2 AI Healthcare Stocks to Buy Right Now

Tempus reported Q4 revenue of $367M, up 83% year-over-year, and is approaching breakeven expected by no later than the year after next; analysts' consensus target of $77.93 implies roughly 70% upside to the current share price. Recursion leverages over 50 petabytes (≈52.4M GB) of chemical and biological data to virtually pretest drug candidates, has begun receiving developmental milestone payments, and expects a significant revenue uplift next fiscal year as AI-powered drug development markets (forecast ~30% CAGR to 2035) expand.

Analysis

AI-enabled discovery is shifting value from isolated R&D labs to firms that combine proprietary clinical-grade data, regulated workflows, and scalable compute. That creates a two-tier market: a small set of firms with exclusive, longitudinal health datasets and integrated wet-lab pipelines will capture outsized deal and milestone economics, while many model-only players will struggle to monetize predictions without downstream regulatory/clinical validation.

Compute and cloud economics are the lever here — companies that own the fast-path to GPU/accelerator cycles and optimized stacks (and can monetize high-margin inference for partners) will see revenue per researcher expand materially, compressing returns for legacy silicon providers that can’t match price/perf. Expect episodic capex waves tied to model retrain cycles and pivotal trial starts, which are measurable 6–18 month cadence events that will show up as discrete revenue spikes for cloud and accelerator vendors.

Regulatory and data-governance friction is the wild card: FDA clarity on AI-inferred endpoints, patient-consent regimes, and reproducibility standards could slow deal conversion by 12–36 months, creating windows where downstream partners renegotiate economics or bring work in-house. On the margin, this favors diversified pharma and exchange operators who profit from higher issuance/M&A activity versus pure-play prediction vendors whose valuations already price in rapid clinical translation.

Key Decisions for Investors

• Pair trade (6–18 months): Long NVDA (accumulate into weakness) / Short INTC (size ~1:1 by notional). Rationale: capture secular premium for GPU-accelerated inference and data-center share gains; target asymmetric return of 2–3x on NVDA if AI compute adoption continues, with INTC downside of 20–35% if it fails to close performance gap. Risk: NVDA multiple already rich—use 30–40% stop or hedge with out-of-the-money calls.
• Options play on market microstructure tailwind (9–15 months): Buy NDAQ Jul-2027 1–2x call spread (sell higher strike) to express pick-up in listing and M&A flow from increased biotech financing and milestone-driven deal activity. R/R: limited premium for ~30–60% upside if issuance volume rises; downside limited to premium paid. Catalyst: heightened IPO/secondary activity, large biotech M&A.
• Long defensive pharma exposure (12–24 months): Accumulate SNY with a 12–24 month horizon to capture steady cash flow and optionality from partnering/outsourcing of AI-enabled programs. R/R: modest upside of 20–40% plus dividend cushion; risk is execution on pipeline and margin compression from technology reinvestment—size accordingly and use a 15% stop-loss.
• Hedge/spec short (3–9 months): Buy put spreads on small-cap AI-drug-discovery names or short an over-concentrated biotech basket to hedge valuation risk—target 20–40% notional of core long exposure. Rationale: many model-first companies face 12–36 month realization risk and funding winter sensitivity; payoff if the market re-rates growth durability. Risk: binary positive trial wins can spike individual names—keep position sizes small and use spreads to cap premium.